VTYX vs. VRCA, KMDA, ORGO, CRMD, NLTX, VNDA, AVIR, URGN, NKTX, and PROC
Should you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Verrica Pharmaceuticals (VRCA), Kamada (KMDA), Organogenesis (ORGO), CorMedix (CRMD), Neoleukin Therapeutics (NLTX), Vanda Pharmaceuticals (VNDA), Atea Pharmaceuticals (AVIR), UroGen Pharma (URGN), Nkarta (NKTX), and Procaps Group (PROC). These companies are all part of the "pharmaceutical preparations" industry.
Ventyx Biosciences (NASDAQ:VTYX) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, community ranking, valuation and risk.
Verrica Pharmaceuticals has higher revenue and earnings than Ventyx Biosciences. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks.
Ventyx Biosciences presently has a consensus target price of $21.75, suggesting a potential upside of 359.83%. Verrica Pharmaceuticals has a consensus target price of $13.50, suggesting a potential upside of 55.71%. Given Ventyx Biosciences' higher possible upside, analysts plainly believe Ventyx Biosciences is more favorable than Verrica Pharmaceuticals.
Ventyx Biosciences has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500.
Verrica Pharmaceuticals received 136 more outperform votes than Ventyx Biosciences when rated by MarketBeat users. Likewise, 64.94% of users gave Verrica Pharmaceuticals an outperform vote while only 49.09% of users gave Ventyx Biosciences an outperform vote.
97.9% of Ventyx Biosciences shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 24.4% of Ventyx Biosciences shares are held by insiders. Comparatively, 42.6% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Verrica Pharmaceuticals had 12 more articles in the media than Ventyx Biosciences. MarketBeat recorded 18 mentions for Verrica Pharmaceuticals and 6 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 0.65 beat Verrica Pharmaceuticals' score of 0.53 indicating that Ventyx Biosciences is being referred to more favorably in the media.
Ventyx Biosciences has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -905.83%. Ventyx Biosciences' return on equity of -65.94% beat Verrica Pharmaceuticals' return on equity.
Summary
Verrica Pharmaceuticals beats Ventyx Biosciences on 9 of the 17 factors compared between the two stocks.
Get Ventyx Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ventyx Biosciences Competitors List
Related Companies and Tools
